4.7 Article

Searching for improved mimetic peptides inhibitors preventing conformational transition of amyloid-β42 monomer

Journal

BIOORGANIC CHEMISTRY
Volume 81, Issue -, Pages 211-221

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bioorg.2018.08.018

Keywords

Mimetic peptides; Alzheimer's disease; Amyloid beta-peptide; A beta aggregation; Molecular dynamics; Molecular docking

Funding

  1. Universidad Nacional de San Luis (UNSL)
  2. Agencia Nacional de Promocion Cientifica y Tecnologica [PICT 2015-1769]
  3. CONICET
  4. ANPCyT
  5. UNR
  6. CONICET (Consejo Nacional de Investigaciones Cientificas y Tecnicas, Argentina)
  7. Hungarian government [GINOP-2.3.2-15-2016-00034]
  8. Hungarian Scientific Research Fund (OTKA) [K111862]

Ask authors/readers for more resources

A series of novel mimetic peptides were designed, synthesised and biologically evaluated as inhibitors of A beta(42) aggregation. One of the synthesised peptidic compounds, termed compound 7 modulated A beta(42) aggregation as demonstrated by thioflavin T fluorescence, acting also as an inhibitor of the cytotoxicity exerted by A beta(42) aggregates. The early stage interaction between compound 7 and the A beta(42) monomer was investigated by replica exchange molecular dynamics (REMD) simulations and docking studies. Our theoretical results revealed that compound 7 can elongate the helical conformation state of an early stage A beta(42) monomer and it helps preventing the formation of beta-sheet structures by interacting with key residues in the central hydrophobic cluster (CHC). This strategy where early on-pathway events are monitored by small molecules will help the development of new therapeutic strategies for Alzheimer's disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available